Blood typing has become a routine test item of clinical blood transfusion department and clinical laboratory, which includes ABO blood group, Rh blood group, and cross-matching of blood test.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Skin disease diagnostics company Castle Biosciences said on Tuesday that it has signed a definitive agreement to acquire Cernostics, a privately held firm that specializes in spatial biology and artificial intelligence-driven image analysis of tissue biopsies.

The US Food and Drug Administration last week granted Emergency Use Authorization for Lighthouse Lab Services' CovidNow SARS-CoV-2 Assay.

On October 18, 2021, ACROBiosystems listed on Shenzhen Stock Exchange (SZSE) ChiNext. The issue price is RMB 112.5 per share, and the opening price is RMB 198 per share. The total amount of funds to be raised is 2.25 billion yuan.

Type 1 Diabetes Mellitus (T1DM) is an autoimmune disease that occurs due to destruction of the islets of Langerhans in the pancreas. These islets contain β cells and when destroyed, it reduces the body’s ability to produce insulin leading to hyperglycemia.

Roche said on Friday that it has signed a development and distribution agreement with PathAI to work on artificial intelligence-based digital pathology applications.

Research has shown that an oxidation-antioxidant imbalance in the blood is an early indicator of Alzheimer's disease, rather than a consequence.

FDA clearance for a watch it says is capable of detecting atrial fibrillation through a medical-grade ECG and measuring blood oxygen levels from the wrist.

The European Union is proposing to delay the go-live date for the incoming medical device regulation pertaining to In Vitro Diagnostics for products that still need assessment of a notified body.

Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, announced today that it has signed a definitive agreement to acquire Bolder Surgical, a privately held, U.S.-based company that provides advanced energy vessel sealing surgical devices, for approximately $160 million.

Agilent Technologies Inc. today announced its Ki-67 IHC MIB-1 pharmDxis now FDA approved as an aid in identifying patients with early breast cancer at high risk of disease recurrence, for whom adjuvant treatment with Verzenio® (abemaciclib) in combination with endocrine therapy is being considered.